No Data
No Data
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Biogen Is Maintained at Outperform by BMO Capital
Biogen Analyst Ratings
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $230
Express News | Biogen : BMO Cuts Target Price to $230 From $260
Express News | Biogen: Eisai to Request Reconsideration of Decision Within 90 Days to Make Lecanemab Available for Eligible People Living With Early Ad in Australia
No Data
No Data
webguybob : The Etsy downgrade surprised me!
105535782 : ok
102242135 Lim : K